CD20/MS4A1: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It’s the GeneMedi’s summary page for Target/Biomarker Introduction of CD20/MS4A1. The page also collects GeneMedi’s different modalities and formats products for CD20 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi’s target-insight database-GM ITD database, the CD20 target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

This gene encodes a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. This gene encodes a B-lymphocyte surface molecule which plays a role in the development and differentiation of B-cells into plasma cells. This family member is localized to 11q12, among a cluster of family members. Alternative splicing of this gene results in two transcript variants which encode the same protein. [provided by RefSeq, Jul 2008]

Target ID

GM-T73215

Target Name

CD20

Gene ID

931

Gene Official Name

MS4A1

Gene Alias

B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7

Protein Sub-location

Transmembrane Protein

Category

Therapeutics Target, Immuno-oncology Target, INN Index

Pre-made CD20-specific INN-index biosimilar (antibody&conjugates)-Mosunetuzumab, Obinutuzumab, ibritumomab tiuxetan, Eramkafusp, Divozilimab, Odronextamab, Ocaratuzumab, Glofitamab, Plamotamab, Veltuzumab, Zuberitamab, eramkafusp alfa, Ofatumumab, Epcoritamab, Ocrelizumab, Afutuzumab, Blontuvetmab, technetium (99mTc) nofetumomab merpentan, tositumomab, Ublituximab, Ripertamab, Rituximab, epitumomab

Anti-CD20 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Filters Sort results
Reset Apply
Cat No.
Products Name (INN Index)
INN Name
Previous Name
Target
Format
Order
Pre-Made Afutuzumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
Afutuzumab
Obinutuzumab
MS4A1/CD20
Whole mAb
Pre-Made Blontuvetmab biosimilar, Canine Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
Blontuvetmab
NA
MS4A1/CD20
Canine Whole mAb
Pre-Made Divozilimab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
Divozilimab
NA
MS4A1
Whole mAb
Pre-Made Envafolimab biosimilar, Single Domain Variable Fragment;H, Anti-CD274/PD-L1 Antibody: Anti-B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, hPD-L1 therapeutic antibody
Epcoritamab
NA
CD3E,MS4A1
Bispecific mAb
Pre-Made Eramkafusp biosimilar, Whole mAb Fusion, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
Eramkafusp
NA
CD20
Whole mAb Fusion
Pre-Made Glofitamab biosimilar, Bispecific mAb with Domain Crossover, Anti-CD3E;MS4A1/CD20 antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7therapeutic antibody
Glofitamab
NA
CD3E,MS4A1
Bispecific mAb with Domain Crossover
Pre-Made Mosunetuzumab biosimilar, Bispecific mAb, Anti-CD3E;MS4A1/CD20 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
Mosunetuzumab
NA
CD3E,MS4A1
Bispecific mAb
Pre-Made Obinutuzumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
Obinutuzumab
Afutuzumab
MS4A1
Whole mAb
Pre-Made Ocaratuzumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
Ocaratuzumab
NA
MS4A1
Whole mAb
Pre-Made Ocrelizumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
Ocrelizumab
NA
MS4A1
Whole mAb
Pre-Made Odronextamab biosimilar, Bispecific mAb, Anti-MS4A1/CD20;CD3E Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7;T3E/TCRE/IMD18 therapeutic antibody
Odronextamab
NA
MS4A1,CD3E
Bispecific mAb
Pre-Made Ofatumumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
Ofatumumab
NA
MS4A1
Whole mAb
Pre-Made Plamotamab biosimilar, Bispecific Mixed mAb and scFv, Anti-MS4A1/CD20;CD3E Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7;T3E/TCRE/IMD18 therapeutic antibody
Plamotamab
NA
MS4A1,CD3E
Bispecific Mixed mAb and scFv
Pre-Made Ripertamab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
Ripertamab
NA
MS4A1
Whole mAb
Pre-Made Rituximab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
Rituximab
NA
MS4A1
Whole mAb
Pre-Made Ublituximab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
Ublituximab
NA
MS4A1
Whole mAb
Pre-Made Veltuzumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
Veltuzumab
NA
MS4A1
Whole mAb
Pre-Made Zuberitamab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
Zuberitamab
NA
MS4A1
Whole mAb
Pre-Made Technetium (99Mtc) Nofetumomab Merpentan Biosimilar, Radiolabelled Antibody: Anti-MS4A1/CD20 therapeutic antibody
technetium (99mTc) nofetumomab merpentan
NA
MS4A1
Radiolabelled antibody
Pre-Made Tositumomab Biosimilar, Radiolabelled Antibody, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
tositumomab
NA
MS4A1
Radiolabelled antibody
Pre-Made Epitumomab Biosimilar, Whole Mab, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
epitumomab
NA
MS4A1
Whole mAb
Pre-Made Eramkafusp Alfa Biosimilar, Fusion Protein targeting MS4A1/CD20 fused with human IFNA2 (interferon alpha 2) via a peptidyl linker: Recombinant therapeutic protein targeting B1/Bp35/CVID5/FMC
eramkafusp alfa
NA
MS4A1
Fusion Protein
Pre-Made Ibritumomab Tiuxetan Biosimilar, Radiolabelled Antibody, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
ibritumomab tiuxetan
NA
MS4A1
Radiolabelled antibody

Anti-CD20/ MS4A1/ B1 antibody for FACS & in-vivo assay| GMab

Pre-made anti-CD20 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CD20 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Filters Sort results
Reset Apply
Cat No.
Antibody Name
Format
Classified by tag
Order
Anti-CD20/MS4A1 monoclonal antibody
mab
FACS/Biofunctional Antibody, Therapeutics Target antibody